A Phase 2, Double-Blind, Placebo-Controlled Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Benralizumab (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 11 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017.
- 16 May 2016 New trial record